Advancements in Device Therapy for Heart Failure, The Rutgers New Jersey medical School and Arrhythmia Institute at University Hospital Experience
Dr. Emad F. Aziz is a top Cardiac Electrophysiologist in New Jersey. With a passion for the field and an unwavering commitment to their specialty, Dr. Emad F. Aziz is an expert in changing the lives of their patients for the better. Through their designated cause and expertise in the field, Dr. Emad F. Aziz is a prime... more
Revolutionizing Heart Failure Management: The Rise of Cardiac Contractility Modulation (CCM)
In the realm of cardiovascular health, innovation is a beacon of hope for millions affected by heart failure. Among the array of groundbreaking advancements, Cardiac Contractility Modulation (CCM) stands out as a revolutionary approach, offering new avenues for managing this chronic condition. At the forefront of this innovation are devices like the Impulse Dynamics Optimizer and Optimizer Mini, heralding a new era in heart failure management.
CCM operates on a simple yet profound principle: by delivering non-excitatory electrical signals to the heart during the absolute refractory period, it enhances cardiac contractility without triggering a new heartbeat. This unique mechanism offers a promising alternative for patients whose conditions are not adequately addressed by traditional therapies.
The Impulse Dynamics Optimizer® and Optimizer Mini represent the pinnacle of CCM technology. These implantable devices work tirelessly to optimize cardiac function, thereby improving patients' quality of life and reducing hospitalizations. Their compact designs and advanced features make them invaluable assets in the fight against heart failure.
Recent clinical trials, such as the AIM Higher trial, have shed light on the efficacy of CCM in managing various forms of heart failure, including diastolic heart failure—a subtype notoriously challenging to treat. The results have been nothing short of remarkable, demonstrating significant improvements in exercise tolerance, symptoms, and overall well-being among participants.
Moreover, University Hospital serve as a hub of education and training, equipping healthcare professionals with the knowledge and skills needed to leverage CCM and similar innovations effectively. By staying at the forefront of medical research and embracing emerging technologies, our institution empowers our faculty to deliver unparalleled care to patients battling heart failure. As we continue to harness the power of innovation, we move closer to a future where heart failure is not just managed but conquered, one heartbeat at a time.
|
Dr. Aziz's pioneering work with the early adoption of Impulse Dynamic Optimizer CCM therapy at University Hospital has yielded impressive outcomes, particularly for patients with an ejection fraction (EF) between 25 to 45%. His documented and published results showcase the effectiveness of this therapy in improving cardiac function within this patient population. What's particularly notable is Dr. Aziz's innovative approach in utilizing CCM therapy in patients with an EF less than 35% prior to undergoing an implantable cardioverter-defibrillator (ICD) implantation. By implanting Optimizer® and employing LifeVEST® as an interim measure. Dr. Aziz effectively managed these patients, resulting in a significant proportion experiencing an increase in their ejection fraction within six months with CCM therapy. This success meant that many of these patients no longer required an ICD implantation, highlighting the potential of CCM therapy destination treatment. Furthermore, great collaboration with Dr. Pallavi Solanki director of heart failure, Dr. Aziz's team and the dedication of the research team led by Jaime Lau, RN, are evident in their achievements, such as leading recruitment efforts for the Optimizer PAS trial, where they secured the 4th position nationwide. Current Indication: The OPTIMIZER® Smart System, delivers the CCM therapy, is indicated to improve 6-minute hall walk distance, quality of life, and functional status of NYHA Class III heart failure patients, who remain symptomatic despite guideline directed medical therapy, who have an LVEF ranging from 25% to 45%.
|
